CFAR Supplement Announcement in HIV/AIDS- FY2012

 

The NIH is interested in supplement applications from CFARs in the following scientific areas:

  1. HIV-TB Co-infection
  2. Ethical Issues in HIV/AIDS Research Involving Specimens

Attached is the CFAR supplement announcement for more details on the above scientific areas of interest.  The key aspects of this funding opportunity are:

  • The deadline for applications to be received at NIAID is May 14, 2012
  • Budget requests vary by scientific area as described in the announcement
  • Funding will be for one year
  • Project directors must be new investigators or established investigators in non-HIV fields who have never received an R01 in HIV/AIDS
  • Potential applicants must have at least one year of funding in the parent grant in June to be eligible to apply to this announcement (CFARs in a bridge year or in a no cost extension are not eligible.)
  • One application is allowed per CFAR per scientific area of interest
  • The earliest start date is 6/15 but may be delayed due to administrative issues

Please note that the number of applications that will be funded for this administrative supplement announcement will be based on funding availability and scientific merit.

Download supplement announcement here: [Download not found]

CDC: HIV Surveillance Report 2010, Vol. 22

Today, the Centers for Disease Control and Prevention (CDC) released its HIV Surveillance Report, 2010, Vol. 22.  This report presents data for diagnoses of HIV infection and AIDS through December 31, 2010 and reported to CDC through June 2011.

CDC’s 2010 HIV Surveillance Report is used by epidemiologists, researchers, and public health practitioners across a wide variety of institutions to help guide program planning, evaluation, and resource allocation.  The surveillance report contains data collected throughout the United States and six U.S. dependent areas by HIV surveillance programs in state and local health departments. It is one of the primary sources of information on HIV in the United States.

We are pleased to note that there are now 51 areas (46 states and five dependent areas) that have had confidential, name-based HIV infection reporting long enough (i.e., since at least January 2007, with reporting to CDC since at least June 2007) to be included in the 2010 HIV Surveillance Report.  The 46 states represent approximately 92% of cumulative AIDS diagnoses in the 50 states and the District of Columbia through 2010.  New states included in this year’s report are California, Delaware, Montana, Oregon, Rhode Island, and Washington (state).

AIDS data from all 50 states, the District of Columbia, and six U.S. dependent areas are included in the report. AIDS data from one US dependent area, the Republic of Palau, are included for the first time in this report.

The 2010 HIV Surveillance Report shows, from 2007 through 2010,

  • The annual estimated number and rate of diagnoses of HIV infection remained stable in the 46 states (i.e., there was less than a 5% increase or decrease from 2007 through 2010), even though estimated numbers and rates of diagnoses of HIV infection increased in some subgroups and decreased in others. CDC estimates that there were 47,129 diagnoses of HIV infection in the 46 states in 2010. The estimated rate of diagnoses of HIV infection the 46 states in 2010 was 16.1 per 100,000 persons.
  •  The annual estimated number of AIDS diagnoses in the United States remained stable, and the rate of annual AIDS diagnoses decreased (based on data from the 50 states, and

the District of Columbia). CDC estimates there were 33,015 AIDS diagnoses in 2010. The estimated rate of AIDS diagnoses in the United States the same year was 10.8 per 100,000 persons.

  • From the beginning of the epidemic through 2010, there have been 1,129,127 persons diagnosed with AIDS in the United States.
  • The majority of diagnoses of HIV infection were among blacks/African Americans (46% of all diagnoses of HIV infection), whites (29%), and Hispanics/Latinos (20%). The only racial/ethnic group to have an increase in the rate of HIV diagnoses was American Indians/Alaska Natives.
  • By transmission category, the only increase seen in the number of HIV diagnoses was among adult and adolescent males with infection attributed to male-to-male sexual contact.

 

The 2010 HIV Surveillance Report shows a 10% increase in the number of HIV diagnoses among persons aged 15-19 years and a 33% increase among persons aged 20-24 years. The fact that our young people are bearing a significant burden of the nation’s HIV infections has been highlighted in recent CDC publications of HIV incidence and a recent CDC surveillance supplemental report focusing on diagnoses of HIV infection among adolescents and young adults. HIV continues to have a significant effect on young people in the United States, especially young men who have sex with men.

Click HERE to see the whole HIV Surveillance Report, 2010, Vol. 22.  

HIV Speeds Lung Function Decline in Cohort of Smokers

CROI 2012

 HIV is an independent risk factor for lung disease, according to new data reported Wednesday, March 7, at the 19th Conference on Retroviruses and Opportunistic Infections. Though the study results from a Johns Hopkins University School of Medicine team note that people living with HIV—particularly those with viral loads not being kept in check with antiretroviral (ARV) therapy—have reduced lung strength and a more rapid loss of pulmonary function compared with HIV-negative controls, the researchers also point out that cigarette smoking was very common in the cohort studies and remains an important risk factor to contend with.

Click HERE to see the full article by Tim Horn on POZ.com

National Women and Girls HIV/AIDS Awareness Day- MARCH 10 2012

National Women and Girls HIV/AIDS Awareness Day is a nationwide observance that encourages people to take action in the fight against HIV/AIDS and raise awareness of its impact on women and girls. It is coordinated by the U.S. Department of Health and Human Services’ Office on Women’s Health (OWH). It helps organizations across the country come together to offer support, encourage discussion, and teach women and girls about prevention of HIV, the importance of getting tested for HIV, and how to live with and manage HIV/AIDS.

National Women and Girls HIV/AIDS Awareness Day is observed specifically on March 10 every year, but OWH encourages organizations to hold events throughout the month of March.

Find out what you can do! Read the OWH Director’s Dear Colleague letter(PDF, 166 KB).

Learn more about National Women and Girls HIV/AIDS Awareness Day.

Penn Study Shows 1 in 4 U.S. HIV Patients Don't Stay in Care

More Than Half of HIV Patients Found to Have Long Gaps in Between Appointments

PHILADELPHIA — Only about 75 percent of HIV/AIDS patients in the United States remain in care consistently, according to new research from the Perelman School of Medicine at the University of Pennsylvania published online this week in AIDS. The study of patients across the United States is the first to provide a comprehensive national estimate of HIV care retention and information about patients who are most likely to continue their treatment over time.

“Helping patients with HIV stay in care is a key way to reduce their chances of getting sick from their disease and prevent the spread of HIV in the community. Our findings show that too many patients are falling through the cracks,” says the study’s lead author, Baligh R. Yehia, MD, a fellow in the division of Infectious Disease and the Health Policy Research Program at Penn Medicine. “The benefits of keeping patients in care are clear both for patients and the community at large, and it may even result in decreased health care costs by preventing unnecessary hospitalization for an acute illness.”

The researchers studied 17,425 adult patients cared for at 12 clinics within the HIV Research Network, a consortium that cares for HIV-infected patients across the nation, between 2001 and 2008. Just 42 percent of patients studied had what researchers defined as “no gap” in treatment — intervals of no more than six months in between outpatient visits — over the timeframe studied, while 31 percent had one or more seven- to 12-month gaps in care. Twenty-eight percent appeared to have gone without care for more than a year on one or more occasions. Since there is no gold standard on the best way to measure retention in care, the team used three different measures of retention to examine each patient’s visit record.

Women, white patients, older patients, male patients who were infected via sex with men, and patients who began treatment on Medicare (compared to those on private insurance) were all more likely to remain in care more consistently. Retention was also greater among patients whose CD4 counts — the measure of how advanced the disease is — were very low, at the point associated with AIDS, when they entered care.

The team suggests that their findings may help guide clinicians in assessing which patients are more likely to follow their prescribed visit schedule, and develop intervention strategies to improve their chances of adhering to their care. “Clinicians need to know what barriers to screen for, so our findings help to better define groups of patients who may require extra help to stay on track,” says the study’s senior author and Yehia’s mentor, Kelly Gebo, MD, an associate professor of Medicine at the Johns Hopkins University School of Medicine. Housing, transportation and financial problems, substance abuse and mental illness can all be contributors to problems with care retention, and patients who don’t have symptoms may not believe they’re “sick” enough to require regular visits with their providers.

Yehia also notes that a standardized criteria for determining the appropriate time between visits is needed, since patients who are at various stages in their disease, have other health conditions or certain social circumstances may require unique plans for care — thus making it hard to assess aggregate retention across the entire HIV population. And since patients may switch doctors, move frequently, go to jail or become institutionalized and still receive care during those times, the research team suggests additional studies that track patients across those circumstances, such as research involving data from insurance records.

Questions also remain about how HIV treatment retention may change as time passes during what has become, for many, a chronic condition spanning decades of their lives.

“It’s possible that as time goes by, some patients may become more regular users of care, while others may become complacent and skip appointments,” Yehia says. “We need to better pinpoint times when certain patients may be less likely to remain in treatment and find ways to ensure their continued care.”

In addition to Yehia and Josh Metlay, MD, PhD, also from Penn, other authors of the paper include investigators from Hopkins, Oregon Health and Sciences University, and the Agency for Healthcare Research and Quality.

 

News release courtesy of Penn Medicine.

New IAPAC Recommendations on Getting and Keeping People in Care for HIV

Addressing a key issue in the HIV/AIDS epidemic, the International Association of Physicians in AIDS Care (IAPAC) has released “Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations.” The recommendations were published March 5 ahead of print in the Annals of Internal Medicine.
While it is well established that entering care immediately after an HIV diagnosis, staying in care and adhering to antiretroviral (ARV) therapy are necessary steps on the road to successfully controlling the virus, figuring out how to ensure that people living with the virus take these steps has turned out to be a challenge. The Centers for Disease Control and Prevention (CDC) estimates that only half of people living with HIV in the United States are receiving regular medical care, and far fewer have their virus under control with ARVs. Numerous studies have been undertaken to address this challenge. Until now, they have not been compiled and assessed based on their results.

 

Read the full AIDSmeds article HERE.

UK physicians conlude that PrEP needs more study before being provided

A position statement by the British HIV Association (BHIVA) and the British Association for Sexual Health and HIV (BASHH) has concluded that as yet the data on the efficacy of pre-exposure prophylaxis (PrEP) is not compelling enough for it to be offered to patients on demand, and that it should only be prescribed in the context of a clinical research study until more data on its efficacy is gathered.

The BHIVA/BASHH position contrasts with that of the US Centers for Disease Control, which issued guidance for doctors prescribing PrEP to patients last year.

The two UK organisations, which represent HIV and STI healthcare workers respectively, conducted a consultation on PrEP last year which included in-person and telephone conferences with a variety of UK treatment and prevention stakeholders in the UK (including NAM), and the creation of an ongoing PrEP Working eGroup.

The finalised position statement notes that in 2010 there was the highest-ever number of new HIV infections in gay men in the UK (over 3000, 81% acquired here) and adds that this “continued increase in infections…underscores the urgent need to…rethink our overall strategy for HIV prevention at a time when the NHS is undergoing change.”

It also however notes that the data on the efficacy of PrEP has so far been widely disparate (see Aidsmap reports on the iPrExPartnersPrEP, TDF2FemPrEP and VOICE trials), in contrast to convincing evidence both for the efficacy of condoms when used consistently and correctly and of treatment as prevention.

It also notes that these are many unanswered questions in the case of PrEP: will it be affordable and cost-effective? Will it increase the likelihood of drug resistance? Are there long-term toxicity concerns for HIV-negative people taking it? And will it induce people to abandon condom use? It also notes there has never been a systematic evaluation of behaviour-change programmes in the UK, also in contrast to the US.

It concludes that “it is imperative to gather [more] evidence for the value of PrEP in the UK” and that therefore “We recommend that ad hoc prescribing is avoided, and that PrEP is only prescribed in the context of a clinical research study”. Until then, “regular HIV testing, the diagnosis and treatment of other STIs, and intensive health promotion activities…should be implemented in preference to PrEP.”

CLICK HERE to read this article by Gus Cairns on aidsmap.com

Amidst Funding Cuts, High NYC HIV Prevalence Found

A 2011 study of gay and bisexual men living in New York City found high rates of unsafe sex and high rates of drug and alcohol use.

The National HIV Behavioral Surveillance Study interviewed 510 men at bars, parks, gyms, and other venues. The men ranged in age from 18 to over 50, though 52 percent were between 18 and 29. Twenty-three percent were African-American, 39 percent were Latino, 29 percent were white, and nine percent identified themselves as “other.”

Of the 510, 448 discussed when they last had unprotected anal sex. Fifty-eight percent of the Latino men said they had such sex in the prior year, and 37 percent of all the Latino men said they had unprotected anal sex during their most recent sexual encounter.

Fifty-one percent of the white men said they had unprotected anal sex in the prior year, as did 51 percent of the men who identified as other. Thirty-two percent of the white men and 31 percent of the “other” men reported having had unprotected anal sex during their last sexual encounter.

Among the African-American men, 45 percent reported unprotected anal sex in the year before the interview, and 23 percent they had such sex during their last sexual encounter.

There is a correlation between unsafe sex and alcohol and drug use, and the men in this study were no exception to that well established relationship.

 

 

To read the full Gay City News article click here.

CDC REPORT: HIV Infection and HIV-Associated Behaviors Among Injecting Drug Users

CDC: Morbidity and Mortality Weekly Report (MMWR)

Injection Drug Users (IDUs) in the United States (U.S.) are at increased risk of acquiring human immunodeficiency virus (HIV) infection. Despite a recent reduction in the number of HIV infections attributed to injecting drug use in the U.S., IDUs remain a substantial proportion of those becoming infected with HIV. In 2009, 9% of new HIV infections in the U.S. occurred among IDUs.

To monitor HIV-associated behaviors and HIV prevalence among IDUs, CDC’s National HIV Behavioral Surveillance System (NHBS) conducts interviews and HIV testing in selected metropolitan statistical areas (MSAs). NHBS is a behavioral surveillance system used to monitor prevalence and trends in 1) HIV-related risk behaviors, 2) HIV testing, and 3) use of HIV prevention services among populations at high risk for acquiring HIV, including MSM, injection-drug users, and heterosexuals at increased risk for HIV infection. Data are collected in annual cycles from one risk group per year so that each group is surveyed once every 3 years. This report summarizes data from 10,073 IDUs interviewed and tested in 20 MSAs in 2009 as part of NHBS.

The report shares increased evidence of risk behaviors for persons at high risk for HIV infection. Of IDUs recruited in 20 U.S. cities, 9% tested positive for HIV, of whom 45% were unaware of their infection. Among those at risk of acquiring HIV infection, 34% reported sharing syringes and 69% reported having unprotected vaginal sex in the past 12 months. Less than half the IDUs reported having been tested for HIV (49%) or participating in a behavioral intervention (19%) during the same time period. HIV infection among IDUs in the U.S. remains a significant challenge. Although incidence data show that HIV incidence among IDUs is low, these data suggest that risk behaviors and lack of awareness of infection remain high.

Given the prevalence of drug and sexual risk behaviors among IDUs, efforts should be made to provide HIV prevention for IDUs – such as increased access to HIV testing, sterile syringes, and condoms.  Multiple reviews find that Syringe Exchange Programs (SEPs) can reduce needle sharing among IDUs, resulting in positive behavior change that can reduce HIV transmission. The reviews also note that SEPs do not result in negative consequences such as increases in injection frequency, in injection drug use, or in unsafe disposal of needles in the community.  SEPs can also provide a positive pathway to prevention for substance abusing persons. Proven prevention strategies remain critical for those at high risk for HIV, such as individuals with multiple sex partners, those in relationships with HIV-positive individuals and IDUs.

 Click here to read the full report

British HIV Association Guidelines for Treatment and Prevention

The British HIV Association (BHIVA) today recommends that doctors should discuss the evidence for the effectiveness of antiretroviral treatment as prevention with all patients with HIV, and that it should be offered those who want to protect their partners from the risk of HIV infection – even if they have no immediate clinical need for treatment themselves.

See a review of these guidelines on Aidsmap.com